Your browser doesn't support javascript.
loading
Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders.
Ayadi, Noah; Oertel, Frederike C; Asseyer, Susanna; Rust, Rebekka; Duchow, Ankelien; Kuchling, Joseph; Bellmann-Strobl, Judith; Ruprecht, Klemens; Klistorner, Alexander; Brandt, Alexander U; Paul, Friedemann; Zimmermann, Hanna G.
Afiliação
  • Ayadi N; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany/NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, c
  • Oertel FC; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany/NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, c
  • Asseyer S; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany/NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, c
  • Rust R; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany/NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, c
  • Duchow A; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany/NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, c
  • Kuchling J; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany/NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, c
  • Bellmann-Strobl J; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany/NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, c
  • Ruprecht K; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Klistorner A; Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia/ Save Sight Institute, The University of Sydney, Sydney, NSW, Australia.
  • Brandt AU; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany/NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, c
  • Paul F; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany/NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, c
  • Zimmermann HG; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany/NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, c
Mult Scler ; 28(5): 757-767, 2022 04.
Article em En | MEDLINE | ID: mdl-34379018
ABSTRACT

BACKGROUND:

Decreased motion perception has been suggested as a marker for visual pathway demyelination in optic neuritis (ON) and/or multiple sclerosis (MS).

OBJECTIVES:

To examine the influence of neuro-axonal damage on motion perception in MS and neuromyelitis optica spectrum disorders (NMOSD).

METHODS:

We analysed motion perception with numbers-from-motion (NFM), visual acuity, (multifocal (mf)) VEP, optical coherence tomography in patients with MS (n = 38, confirmatory cohort n = 43), NMOSD (n = 13) and healthy controls (n = 33).

RESULTS:

NFM was lower compared with controls in MS (B = -12.37, p < 0.001) and NMOSD (B = -34.5, p < 0.001). NFM was lower in ON than in non-ON eyes (B = -30.95, p = 0.041) in NMOSD, but not MS. In MS and NMOSD, lower NFM was associated with worse visual acuity (B = -139.4, p < 0.001/B = -77.2, p < 0.001) and low contrast letter acuity (B = 0.99, p = 0.002/B = 1.6, p < 0.001), thinner peripapillary retinal nerve fibre layer (B = 1.0, p < 0.001/ B = 0.92, p = 0.016) and ganglion cell/inner plexiform layer (B = 64.8, p < 0.001/B = 79.5, p = 0.006), but not with VEP P100 latencies. In the confirmatory MS cohort, lower NFM was associated with thinner retinal nerve fibre layer (B = 1.351, p < 0.001) and increased mfVEP P100 latencies (B = -1.159, p < 0.001).

CONCLUSIONS:

Structural neuro-axonal visual pathway damage is an important driver of motion perception impairment in MS and NMOSD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neurite Óptica / Neuromielite Óptica / Percepção de Movimento / Esclerose Múltipla Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neurite Óptica / Neuromielite Óptica / Percepção de Movimento / Esclerose Múltipla Idioma: En Ano de publicação: 2022 Tipo de documento: Article